Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Hagop M. Kantarjian, Francis J. Giles, Peter L. Greenberg, Ron L. Paquette, Eunice S. Wang, Janice L. Gabrilove, Guillermo Garcia-Manero, Kuolung Hu, Janet L. Franklin, Dietmar P. Berger

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds